Skip to main content

Clinical Studies

The TPC clinical track carries out clinical trials to rigorously test whether personalised treatment decisions based on biomarker panels improve the clinical outcome, compared to standard treatment. Depending on the resulting findings, predictions from data discovered in the Data Science track will be tested in new clinical trials.

TPC technologies have been applied to 241 tumor samples collected over three years and across three cancer indications:
– metastatic melanoma
– metastatic epithelial ovarian cancer
– acute myeloid leukemia (AML).

The selection of these indications was based on the potential clinical benefit and availability of sufficient tumor material for simultaneous analysis across all technologies.

In addition to multiple bulk approaches, an average of two million single cells per patient were profiled across six technologies with single-cell readouts.

An in-depth analysis of the data acquired at the cohort level, including the clinical outcome of each patient collected over a 6-month follow-up period, is performed in the context of an «Exploratory Science loop», in which the multiscale approach will be used to improve the understanding of the disease and discover novel biomarkers.

If you would like to learn more about the TPC's clinical studies, please contact us This email address is being protected from spambots. You need JavaScript enabled to view it.

You can support the work of the TPC with a donation through the ETH foundation.

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.